PATENT CLAIM ANALYSIS

Application Number: 16032812
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["436", "547000"]

Abstract:
The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

Claim (Index 1):
A method for inhibiting or reducing the severity of retinal ganglion cell (RGC) damage or axonal damage in a subject comprising\n locally administering to an ocular or adnexal tissue of said subject a composition comprising an immunosuppressant agent, thereby inhibiting or reducing the severity of said RGC damage or axonal damage, wherein said subject comprises an elevated level of heat shock protein 27 (hsp27)- or heat shock protein 60 (hsp60)-reactive CD4+ T cells in peripheral blood, whole blood, vitreous humor, or aqueous humor compared to the level of said T cells of an age-matched healthy control; and wherein said agent inhibits autoreactive CD4+ T cells.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 95.0
- Lexical Diversity: 1.13043
- Patent Class: 436.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10807414', '14812566', '11034262', '09765644', '14403523']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6464906934080057
- 35 USC 102 Novelty (BERT): 0.5143130913336766
- Combined Prediction Score: 0.6332729332005729
- Mean Citation Score: 304.389314
- Max Citation Score: 318.16144
- Similarity Product: 218.27456039463044

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test